The study will be carried out in partnership with The GOG Foundation and the European Network of Gynecological Oncological ...

For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated ...

I want to move to a hotter topic in endometrial cancer, and that's really around immunotherapy. You gave the invited discussant presentation at the Society of Gynecologic Oncology (SGO ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

If you have recurrent endometrial cancer, your doctor will talk to you about your treatment options, including radiation, chemotherapy, immunotherapy, or sometimes surgery. (Photo Credit ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

and endometrial cancer" and can also be found in “cancers of the breast, prostate, bladder and thyroid.” The immunotherapy drug works by targeting cells with this mutation, as the ...

Immunotherapy drugs like dostarlimab have been used as a front-line treatment for some metastatic cancers, melanoma, and other cancer types. Dostarlimab was first approved for use in endometrial ...

These immunotherapy drugs effectively remove the “brakes” that cancer cells place on the ... The drug is already approved for treating endometrial cancers with the same genetic mutation.

About 16% of ovarian cancers and as much as 30% of endometrial cancers ... people are being diagnosed with cancer, Cercek said. The research also suggests that immunotherapy could possibly be ...

But she had immunotherapy treatment two years ago ... Only about 16% of ovarian cancer has it, while as much as 30% of endometrial cancer has the mutation, NBC News reported.